We have located links that may give you full text access.
JOURNAL ARTICLE
REVIEW
Antisense oligonucleotides in the treatment of cerebral gliomas. Review of concerning patents.
Recent Patents on CNS Drug Discovery 2014 April
Gliomas are the most common and malignant primary brain tumors in the adult population. Despite the intensive research on cancer pathology, real mechanisms concerning glioma progression are not completely understood. The prognosis in patients affected by malignant gliomas is still very unfavorable. Recent genomic analyses have revealed patterns of molecular changes within tumor subclasses that harbor distinct underlying biology, clinical prognosis, and pathogenic routes. So, novel treatments will have to be able to interfere at different molecular levels in gliomagenesis minimizing the toxicity. In particular, antisense oligonucleotides are able to inhibit expression of specific genes by interfering with transcription or, more usually, with translation. In this review, we will focus on mechanisms of antisense oligonucleotides reporting clinical and experimental studies. We will also report a large number of patents which adopt the antisense oligonucleotides as potential therapeutic approach in gliomas treatment.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app